Effect of Cabergoline on Weight and Glucose Tolerance
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss, Endocrine |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 4/21/2016 |
| Start Date: | April 2002 |
| End Date: | July 2011 |
Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults
The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine
receptor agonist, on body weight and blood glucose in healthy obese adults.
This is a randomized double-blind placebo controlled study. Twenty subjects each will be
randomly assigned either placebo or cabergoline for 16 weeks.
The effect of treatment on body weight and blood glucose and insulin levels will be compared
in the treatment versus the placebo arm.
receptor agonist, on body weight and blood glucose in healthy obese adults.
This is a randomized double-blind placebo controlled study. Twenty subjects each will be
randomly assigned either placebo or cabergoline for 16 weeks.
The effect of treatment on body weight and blood glucose and insulin levels will be compared
in the treatment versus the placebo arm.
Inclusion Criteria:
- age 18 - 55 years
- BMI 30 -40
Exclusion Criteria:
- diabetes,
- clinically significant medical condition,
- use of medications that effect blood glucose or body weight
We found this trial at
1
site
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
Click here to add this to my saved trials
